Epitomee Medical Ltd. completes NIS 162 million IPO on the Tel Aviv Stock Exchange
Categories: Capital Markets
Epitomee Medical Ltd. has completed an IPO on the Tel Aviv Stock Exchange. As part of the IPO, Epitomee raised NIS 162 million for a valuation of NIS 632 million.
Epitomee’s groundbreaking technology allows a patient to receive biological treatment directly to the digestive system, by swallowing a capsule containing small medical devices, instead of intravenously or by injections.
Shibolet advised the issuer, with partner Itshak Cohen-Yehonatan and associate Omer Weiss advising on the IPO.
